IP Library Granted Patent US 8,148,509
Granted Patent B2
US 8,148,509 · App. 12/879,511 · Granted Apr 3, 2012

Transgene delivering retrovirus targeting collagen exposed at site of tissue injury

Assignee: University of Southern California
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,148,509
App. No.
12/879,511
Granted
Apr 3, 2012
Kind
B2
Abstract

A viral or non-viral vector particle having a modified viral surface protein wherein the viral surface protein is modified to include a targeting polypeptide including a binding region which binds to an extracellular matrix component. Such vector particles are useful in delivering genes encoding therapeutic agents to cells located at the site of an exposed extracellular matrix component.

Claims (7)

1. A recombinant modified polynucleotide encoding a modified viral envelope protein for targeting a viral vector to an extracellular matrix, wherein the modified viral envelope protein includes a targeting polypeptide comprising a binding region which binds to collagen.

2. The recombinant modified polynucleotide of claim 1 , wherein said modified viral envelope protein is a modified retroviral envelope protein.

3. The recombinant modified polynucleotide of claim 2 , wherein said modified retroviral envelope protein comprises a modified receptor binding region comprising said targeting polypeptide.

4. The recombinant modified polynucleotide of claim 3 , wherein said modified receptor binding region has the sequence set forth in SEQ ID NO:1 which additionally comprises said targeting polypeptide inserted between amino acid residues 18 and 19 of SEQ ID NO:1.

5. The recombinant modified polynucleotide of claim 1 , wherein the collagen is collagen Type I or collagen Type IV.

6. The recombinant polynucleotide of claim 4 , wherein the binding region of the targeting polypeptide encodes the sequence Trp-Arg-Glu-Pro-Ser-Phe-Met-Ala-Leu-Ser (SEQ ID NO:3).

7. A producer cell for producing retroviral vector particles having a modified envelope protein, said producer cell including the recombinant modified polynucleotide of claim 2 .

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 17, 2011
From: HALL, FREDERICK L.; GORDON, ERLINDA M.
To: UNIVERSITY OF SOUTHERN CALIFORNIA
Reel/Frame 025828/0007 →
Continuity (5)
Continuation 12016847 · Jan 18, 2008
Continuation 11014629 · Dec 15, 2004
Continuation 09904923 · Jul 13, 2001
Continuation 08837223 · Apr 10, 1997
Related Publication 20110065179A1 · Mar 17, 2011